ATFA
MRNA icon

All Terrain Financial Advisors’s Moderna MRNA Stock Holding History

All Terrain Financial Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,300
Closed -$554K – 108
2020
Q4 		$554K Buy
+5,300
New +$536K 0.22% 53

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

All Terrain Financial Advisors's MRNA Position: Q1 2021 in Review

All Terrain Financial Advisors sold out of Moderna (MRNA) in Q1 2021, closing a stake of 5,300 shares — an estimated $554K sold.

All Terrain Financial Advisors first reported a position in MRNA in Q4 2020 and held it in 1 quarter. The position peaked at $554K in Q4 2020. 776 funds tracked by Wall St. Rank hold MRNA as of Q1 2021.

  • All Terrain Financial Advisors reported no remaining Moderna position as of Q1 2021 after selling out during the quarter.
  • All Terrain Financial Advisors sold 5,300 Moderna shares in Q1 2021, an estimated $554K.
  • All Terrain Financial Advisors first reported a position in Moderna in Q4 2020 and held it in 1 quarter.
  • All Terrain Financial Advisors's Moderna position peaked at $554K in Q4 2020.
  • 776 funds tracked by Wall St. Rank held Moderna as of Q1 2021.

Based on All Terrain Financial Advisors's 13F filing for Q1 2021, filed 13 May 2021.